Evaluating short-term and long-term liver fibrosis improvement in hepatitis C patients after DAA treatment
Yifan Wang1
Xinyan Ma2
Yanzheng Zou2
Ming Yue3
Meiling Zhang1
Rongbin Yu2
Hongbo Chen1
Peng Huang2
1.Department of Infectious Disease,Jurong Hospital Affiliated to Jiangsu University,Jurong,Jiangsu 212400,China2.Department of Epidemiology,Center for Global Health,School of Public Health,Nanjing Medical University,Nanjing,Jiangsu 211166,China3.Department of Infectious Diseases,the First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210029,China
摘要：Despite achieving a high cure rate with the direct-acting antivirals(DAAs)in hepatitis C treatment,further research is needed to identify additional benefits of the DAA therapy.The current study evaluated liver fibrosis improvement in 848 hepatitis C patients treated with DAAs,who also achieved sustained virologic response.By the fibrosis-4(FIB-4)index,patients were categorized based on their baseline fibrosis levels,and the improvement in fibrosis was analyzed in both short-term(9-26 weeks)and long-term(≥36 weeks)follow-up.The results showed a significant decrease in the FIB-4 index,indicating an improvement in liver fibrosis,in 63.0%and 67.6%of the patients during the short-term and long-term follow-up,respectively.Short-term improvement was associated with factors including ribavirin usage,blood cholinesterase levels,alanine transaminase levels,albumin levels,and the baseline FIB-4 index,while long-term improvement was associated with factors such as aspartate transaminase levels,total protein level,and the baseline FIB-4 index.The current study emphasizes the importance of continuous assessment and post-treatment monitoring of liver fibrosis,which will provide crucial insights for enhancing patient care in hepatitis C management.
机标关键词：fibrosisafterevaluatinghepatitisimprovementliverlong-termpatients
分类号：R512.63(传染病)
论文发表日期：2024-09-30
在线出版日期：2026-03-31（本平台首次上网日期，不代表文献的发表时间）
页数：10( 中插4,464-472 )
英文信息